Lineage Cell Therapeutics, Inc. (LCTX)
0.82
-0.02
(-2.21%)
USD |
NYAM |
Nov 19, 16:00
0.841
+0.02
(+2.56%)
After-Hours: 07:41
Lineage Cell Therapeutics Enterprise Value : 163.12M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | 163.12M |
| November 18, 2026 | 167.80M |
| November 17, 2026 | 162.05M |
| November 16, 2026 | 156.82M |
| November 13, 2026 | 187.04M |
| November 12, 2026 | 206.19M |
| November 11, 2026 | 236.46M |
| November 10, 2026 | 218.76M |
| November 09, 2026 | 228.87M |
| November 06, 2026 | 213.70M |
| November 05, 2026 | 204.37M |
| November 04, 2026 | 216.23M |
| November 03, 2026 | 211.17M |
| November 02, 2026 | 211.17M |
| October 30, 2026 | 208.64M |
| October 29, 2026 | 216.23M |
| October 28, 2026 | 218.76M |
| October 27, 2026 | 216.23M |
| October 26, 2026 | 207.86M |
| October 23, 2026 | 208.64M |
| October 22, 2026 | 204.85M |
| October 21, 2026 | 196.37M |
| October 20, 2026 | 201.71M |
| October 19, 2026 | 196.70M |
| October 16, 2026 | 203.15M |
| Date | Value |
|---|---|
| October 15, 2026 | 206.19M |
| October 14, 2026 | 187.78M |
| October 13, 2026 | 185.45M |
| October 12, 2026 | 197.03M |
| October 09, 2026 | 207.12M |
| October 08, 2026 | 216.23M |
| October 07, 2026 | 195.39M |
| October 06, 2026 | 192.93M |
| October 05, 2026 | 190.28M |
| October 02, 2026 | 191.01M |
| October 01, 2026 | 184.41M |
| September 30, 2026 | 197.44M |
| September 29, 2026 | 189.98M |
| September 28, 2026 | 195.93M |
| September 25, 2026 | 210.85M |
| September 24, 2026 | 190.06M |
| September 23, 2026 | 192.31M |
| September 22, 2026 | 213.38M |
| September 21, 2026 | 205.79M |
| September 18, 2026 | 210.85M |
| September 17, 2026 | 210.85M |
| September 16, 2026 | 220.96M |
| September 15, 2026 | 218.43M |
| September 14, 2026 | 220.96M |
| September 11, 2026 | 205.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Curis, Inc. | -2.891M |
| Armata Pharmaceuticals, Inc. | 344.10M |
| Voyager Therapeutics, Inc. | 23.80M |
| Black Diamond Therapeutics, Inc. | -6.113M |
| Invivyd, Inc. | 13.16M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.23M |
| Revenue (Quarterly) | 1.434M |
| Total Expenses (Quarterly) | -2.798M |
| EPS Diluted (Quarterly) | -0.0298 |
| Gross Profit Margin (Quarterly) | 85.56% |
| Earnings Yield | -10.24% |
| Normalized Earnings Yield | -18.48 |